



November 5, 2013

## **PTC THERAPEUTICS TO PRESENT AT CREDIT SUISSE ANNUAL HEALTH CARE CONFERENCE**

SOUTH PLAINFIELD, NJ – NOVEMBER 5, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual Health Care Conference on Tuesday, November 12 at 4:30 pm MT.

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at [www.ptcbio.com](http://www.ptcbio.com). The presentation will be archived for two weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

### **ABOUT PTC THERAPEUTICS, INC.**

PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website [www.ptcbio.com](http://www.ptcbio.com)

### **FOR MORE INFORMATION PLEASE CONTACT:**

Jane Baj  
+1 (908) 912-9167   
[jbaj@ptcbio.com](mailto:jbaj@ptcbio.com)

### **FORWARD LOOKING STATEMENTS:**

Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for our product candidates, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.